Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 May 22;10(11):e31471.
doi: 10.1016/j.heliyon.2024.e31471. eCollection 2024 Jun 15.

Targeted variant prevalence of FBXW7 gene mutation in colorectal carcinoma propagation. The first systematic review and meta-analysis

Hafeez Abiola Afolabi  1 , Salzihan Md Salleh  2 , Zaidi Zakaria  1 , Ch'ng Ewe Seng  3 , Norasikin Mohd Nafi  4 , Ahmad Aizat Bin AbdulAziz  5 , Yusuf Wada  6   7 , Ahmad Adebayo Irekeola  6 , Sameer Badri Al-Ml-Hanna  8 , Ali Mussa  9   10
Affiliations

Targeted variant prevalence of FBXW7 gene mutation in colorectal carcinoma propagation. The first systematic review and meta-analysis

Hafeez Abiola Afolabi et al. Heliyon. .

Abstract

FBXW7 is a tumour suppressor gene that functions as E3-ubiquitin-ligase, targeting numerous oncoproteins for degradation, i.e., Cyclin-E, c-Myc, and Notch. FBXW7 performs a pivotal role in regulating cell cycle progression. FBXW7 mutation is frequently implicated in various cancers.

Methodology: A systematic review and meta-analysis done on several studies using "Preferred Reporting Items for Systemmatic Reviews and Meta-Analysis (PRISMA)" criteria and registered with PROSPERO (registration-number-CRD42023388845). The preliminary search comprises 1182 articles; however, 58 studies were subsequently chosen after eliminating non-eligible studies. To explore the prevalence of FBXW7 mutation among colorectal cancer patients, data were analysed using "OpenMeta Analyst and comprehensive meta-analysis-3.0 (CMA-3.0)" software.

Results: This meta-analysis involves 13,974 respondents; most were males 7825/13,974, (56.0 %). Overall prevalence of FBXW7 mutations was 10.3 %, (95%CI: 8.6-12.4), I2 = 90.5 %, (P < 0.001). The occurrence of FBXW7 mutations was highest in Russia [19.0 %, (95%CI: 9.8-33.7)] and Taiwan [18.8 %, (95%CI: 8.7-35.9)], P-values< 0.05 while the least prevalence was reported in Netherland (4 %) and Italy (5 %), both P-values< 0.001. Overall prevalence of FBXW7 abberation was greatest amongst male gender: "53.9 %, (95%CI: 8.3-62.0 %)", Tumour location (colon): 59.8 %, (95%CI: 53.9-65), tumour site (left): 61.6 %, (95%CI: 53.8-68.9), Tumour-grade (Moderate): 65.9 %, (95%CI: 54.9-75.4 %), and Tumour late-stage: 67.9 %, (95%CI: 49.7-84.3 %), all P-values< 0.001. When stratified according to study-period, an increasing trend was noted from 2018 till present with the highest mutation rate recorded in 2022 (15.3 %).

Conclusion: Overall prevalence of FBXW7 mutations was 10.3 % with male gender, left side, and late-stage being most mutated, and these outcomes conform with severally published articles on FBXW7 mutation.

Keywords: CRC; Colon cancer; Colorectal carcinoma; FBXW7 gene mutation.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Figures

Fig. 1
Fig. 1
Summary representation of articles identification and selection process.
Fig. 2
Fig. 2
A Forest plot for the prevalence of FBXW7 mutation in CRC patients.
Fig. 3
Fig. 3
A Forest plot for the prevalence of FBXW7 mutation in CRC patients by countries.
Fig. 3
Fig. 3
A Forest plot for the prevalence of FBXW7 mutation in CRC patients by countries.
Fig. 4
Fig. 4
Geography representation of FBXW7 gene mutation by countries.
Fig. 5
Fig. 5
Graphical representation of FBXW7 gene mutation yearly rate prevalence trend.
Fig. 6
Fig. 6
Funnel Plot. Funnel plot showing no significant publication bias (Egger's p = 0.23771)..
See this image and copyright information in PMC

References

    1. Bray F., Ferlay J., Soerjomataram I., Siegel R.L., Torre L.A., Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA A Cancer J. Clin. 2018;68(6):394–424. - PubMed
    1. Li Y., He X., Ding Y., Chen H., Sun L. Statin uses and mortality in colorectal cancer patients: an updated systematic review and meta‐analysis. Cancer Med. 2019;8(6):3305–3313. - PMC - PubMed
    1. Al-Shamsi H.O., et al. Molecular spectrum of KRAS, NRAS, BRAF, PIK3CA, TP53, and APC somatic gene mutations in Arab patients with colorectal cancer: determination of frequency and distribution pattern. J. Gastrointest. Oncol. 2016;7(6):882. - PMC - PubMed
    1. Poturnajova M., Furielova T., Balintova S., Schmidtova S., Kucerova L., Matuskova M. Molecular features and gene expression signature of metastatic colorectal cancer. Oncol. Rep. 2021;45(4):1. - PMC - PubMed
    1. Montminy E.M., Jang A., Conner M., Karlitz J.J. Screening for colorectal cancer. Med. Clin. 2020;104(6):1023–1036. - PubMed

LinkOut - more resources